Replaces Prod. #: BML-NA137
Lamotrigine blocks voltage-gated sodium channels. Inhibits the release of glutamate. Neuroprotective. Anticonvulsant.
Product Details
| Alternative Name: | 6-(2,3-Dichlorophenyl)-1,2,4-triazine-3,5-diamine, LTG, BW-430C |
| |
| Formula: | C9H7Cl2N5 |
| |
| MW: | 256.1 |
| |
| CAS: | 84057-84-1 |
| |
| MI: | 14: 5353 |
| |
| RTECS: | XY5850700 |
| |
| Purity: | ≥98% (Assay) |
| |
| Identity: | Determined by IR. |
| |
| Appearance: | White to off-white powder. |
| |
| Solubility: | Soluble in DMSO (60°C, 20mg/ml) or dimethyl formamide; slightly soluble in anhydrous ethanol or dilute hydrochloric acid; almost insoluble in water. |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | +4°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy: C. Luna-Tortos, et al.; Neuropharmacology
58, 1019 (2010),
Abstract;
Neuroprotection by lamotrigine in a rat model of neonatal hypoxic-ischaemic encephalopathy: G. Papazisis, et al.; Int. J. Neuropsychopharmacol.
11, 321 (2008),
Abstract;
Lamotrigine is neuroprotective in the energy deficiency model of MPTP intoxicated mice: E. Lagrue, et al.; Pediatr. Res.
62, 14 (2007),
Abstract;
A novel drug binding site on voltage-gated sodium channels in rat brain: D.R. Ridall, et al.; Mol. Pharmacol.
69, 278 (2006),
Abstract;
Full Text
Lamotrigine and its applications in the treatment of epilepsy and other neurological and psychiatric disorders: S. Malik, et al.; Expert Rev. Neurother.
6, 1609 (2006),
Abstract;
Lamotrigine in the treatment of bipolar disorder: Z. Bhagwagar & G.M. Goodwin; Expert Opin. Phamacother.
6, 1401 (2005),
Abstract;
Review of lamotrigine and its clinical applications in epilepsy: H. Choi & M.J. Morrell; Expert Opin. Pharmacother.
4, 243 (2003),
Abstract;
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception: T.M. Laughlin, et al.; J. Pharmacol. Exp. Ther.
302, 1168 (2002),
Abstract;
Full Text
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group: J.R. Calabrese, et al.; J. Clin. Psychiatry
60, 79 (1999),
Abstract;
Cellular and molecular actions of lamotrigine: Possible mechanisms of efficacy in bipolar disorder: X. Xie & R.M. Hagan; Neuropsychobiology
38, 119 (1998),
Abstract;
Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans: A.F. Cohen, et al.; Clin. Pharmacol. Ther.
42, 535 (1987),
Abstract;
Acute effects of lamotrigine (BW430C) in persons with epilepsy: C.D. Binnie, et al.; Epilepsia
27, 248 (1986),
Abstract;
Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats: A.A. Miller, et al.; Epilepsia
27, 483 (1986),
Abstract;
Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: II. Neurochemical studies on the mechanism of action: M.J. Leach, et al.; Epilepsia
27, 490 (1986),
Abstract;
The effect of lamotrigine, a novel anticonvulsant, on interictal spikes in patients with epilepsy: S. Jawad, et al.; Br. J. Clin. Pharmacol.
22, 191 (1986),
Abstract;
Full Text
Lamotrigine (BW430C), a potential anticonvulsant. Effects on the central nervous system in comparison with phenytoin and diazepam: A.F. Cohen, et al.; Br. J. Clin. Pharmacol.
20, 619 (1985),
Abstract;
Full Text
